Results 21 to 30 of about 15,263 (254)

Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.

PLoS ONE, 2022
BackgroundDupilumab is a human antibody that blocks the signaling of both interleukin-4 and interleukin-13 receptors. It has been approved for the treatment of moderate-to-severe atopic dermatitis.
Sunny Park, So Hyang Park, Young Joo Byun, Soo An Choi   +3 more
doaj   +3 more sources

Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient

Journal of Dermatological Treatment, 2023
Uveitis is a rare adverse event of dupilumab, that typically affects both eyes and often leads to discontinuation of therapy. In this article, we report a case of a 28-year-old female with atopic dermatitis who developed new-onset iridocyclitis, a form ...
Shiyu Zhang, Lu Lu, Jindi Feng, Zhonghui Hu, Hongbin Song, Lu Yang, Yuehua Liu, Di Chen, Tao Wang   +8 more
doaj   +1 more source

Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase

Scientific Reports, 2021
Dupilumab is a dual inhibitor of interleukin-4 and interleukin-13 and is mainly used to treat moderate-to-severe atopic dermatitis. Post-marketing safety data related to dupilumab have been accumulated, and it has been found that ocular surface diseases ...
Sunny Park, Jung Hyun Lee, Ji Hyun Park, So Hyang Park, Song Yi Park, Yong Woo Jung, Soo An Choi   +6 more
doaj   +1 more source

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series

Journal of Allergy and Clinical Immunology: Global, 2023
This case series study is the first report of Japanese adolescents who experienced dupilumab facial redness after starting dupilumab treatment for refractory atopic dermatitis.
Shuhei Hara, MD, Takaaki Itonaga, MD, Makoto Nishino, MD, Noriyuki Yanagida, MD, PhD, Sakura Sato, MD, Motohiro Ebisawa, MD, PhD   +5 more
doaj   +1 more source

Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP

BMC Pulmonary Medicine, 2022
Background Dupilumab, an anti-IL-4α receptor antibody, is a new treatment for severe or refractory asthma. However, real-world evidence on the efficacy of dupilumab in patients with mild to moderate bronchial asthma is lacking. Methods We retrospectively
Shunsuke Minagawa, Jun Araya, Naoaki Watanabe, Shota Fujimoto, Junko Watanabe, Hiromichi Hara, Takanori Numata, Kazuyoshi Kuwano, Yoshinori Matsuwaki   +8 more
doaj   +1 more source

Dupilumab‐induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis [PDF]

, 2023
BACKGROUND Dupilumab, a monoclonal anti-IL-4Rα antibody, is approved for several type 2 mediated inflammatory diseases like asthma, atopic dermatitis, and diffuse type 2 chronic rhinosinusitis (CRS).
Steiner, Urs C, Brühlmann, Catrin, Alan Valaperti, Yalamanoglu, Ayla, Stephan Traidl, Michael B. Soyka, Catrin Brühlmann, Soyka, Michael B, Urs C. Steiner, Ayla Yalamanoglu, Fabio S. Ryser, Mauthe, Tina, Tina Mauthe, Valaperti, Alan, Ryser, Fabio S, Traidl, Stephan   +15 more
core   +2 more sources

Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis [PDF]

, 2023
BACKGROUND Chronic rhinosinusitis with a type 2 inflammatory pattern (T2CRS) is believed to be restricted to the nose and sinuses and associated with polyps, without clear serologic markers.
Brühlmann, Catrin, Dülgeroglu, Jacqueline, Michael B. Soyka, Catrin Brühlmann, Peter Schmid‐Grendelmeier, Soyka, Michael B, Urs C. Steiner, Fehr, Danielle, Schmid-Grendelmeier, Peter, Danielle Fehr, Jacqueline Dülgeroglu, Fabio S. Ryser, Steiner, Urs, Marie‐Charlotte Brüggen, Ryser, Fabio S, Brüggen, Marie-Charlotte   +15 more
core   +1 more source

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. [PDF]

, 2021
Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series.
Bossart, Simon, Schlapbach, Christoph, Borradori, Luca, Feldmeyer, Laurence, Seyed Jafari, S. Morteza, Simon, Dagmar   +5 more
core   +2 more sources

Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults

Качественная клиническая практика, 2022
Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib).
A. S. Kolbin, Y. M. Gomon, M. A. Proskurin, Y. E. Balikina   +3 more
doaj   +1 more source